Cybin Inc. (HELP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental ...

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg ...

Helus Pharma Inc., formerly Cybin Inc., provided highlights on the advancement of its lead clinical programs, HLP003 and HLP004, during an investor presentation held on October 21, 2026. The company ...

Cybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth ...

Cybin has made operational progress on several fronts over the last six months; however, these steps are not game-changing, and the company’s big challenges still lie ahead. In the absence of material ...

Cybin updated the market with impressive 12-month efficacy data for its CYB003 Phase 2 trial. Although trial participant numbers were very low, the strength of the new data represents a modest ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cybin Inc. CYBN announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltryptamine ...

Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. - EMBRACE, the second study within the Phase 3 ...

- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pending - - Creates strong synergies by combining ...